Prelude Therapeutics Reports Full Year 2021 Financial Results
16 mars 2022 07h30 HE
|
Prelude Therapeutics, Inc.
Significant progress achieved in 2021: Pipeline now includes six internally discovered small molecule compounds targeting clinically validated pathways in cancers with underserved patients Objectives...
Prelude Therapeutics to Participate at the Barclays 2022 Global Healthcare Conference
11 mars 2022 08h00 HE
|
Prelude Therapeutics, Inc.
WILMINGTON, Del., March 11, 2022 (GLOBE NEWSWIRE) -- Prelude Therapeutics Inc. (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that Kris Vaddi, PhD, Chief Executive...
Prelude Therapeutics Provides Clinical Update and Announces Presentation of New Preclinical Data at the Upcoming 2022 AACR Annual Meeting
09 mars 2022 08h05 HE
|
Prelude Therapeutics, Inc.
Announces strategic prioritization within lead programs targeting PRMT5 and MCL1 Describes new pipeline candidate, PRT3645, a highly brain penetrant CDK4/6 inhibitor;IND submission planned mid-2022 ...
Jane Huang, M.D., Joins Prelude Therapeutics as President and Chief Medical Officer
09 mars 2022 08h00 HE
|
Prelude Therapeutics, Inc.
WILMINGTON, Del., March 09, 2022 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD) a clinical-stage precision oncology company, today announced that Jane Huang, M.D., has been...
Prelude Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference
11 févr. 2022 07h00 HE
|
Prelude Therapeutics, Inc.
WILMINGTON, Del., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Prelude Therapeutics Inc. (NASDAQ: PRLD), a clinical-stage precision oncology company, today announced that Kris Vaddi, PhD, Chief Executive...
Prelude Therapeutics to Present at the H.C. Wainwright BioConnect Virtual Conference
04 janv. 2022 07h00 HE
|
Prelude Therapeutics, Inc.
WILMINGTON, Del., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Prelude Therapeutics Inc. (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that Kris Vaddi, PhD, Chief Executive...
Prelude Therapeutics to Participate at the 4th Annual Evercore ISI HealthCONx Conference
23 nov. 2021 07h00 HE
|
Prelude Therapeutics, Inc.
WILMINGTON, Del., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Prelude Therapeutics Inc. (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that Kris Vaddi, PhD, Chief Executive...
Prelude Therapeutics Announces Third Quarter 2021 Financial Results and Operations Update
12 nov. 2021 08h00 HE
|
Prelude Therapeutics, Inc.
PRT543 and PRT811 Demonstrate Favorable Safety Profile, Tolerability and Evidence of Preliminary Clinical Activity in Phase 1 Dose Escalation in Unselected Patients Phase 1 Dose Expansion Ongoing...
Prelude Therapeutics Announces IND Clearance for PRT2527, a Highly Selective CDK9 Inhibitor
08 nov. 2021 09h00 HE
|
Prelude Therapeutics, Inc.
WILMINGTON, Del., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Prelude Therapeutics Inc. (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that the United States Food and Drug...
Prelude Therapeutics Announces Presentation of Encouraging Data from Multiple Programs at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics
07 oct. 2021 09h00 HE
|
Prelude Therapeutics, Inc.
– Lead oral PRMT5 inhibitors PRT543 and PRT811 demonstrate favorable safety profile, evidence of preliminary clinical activity including durable responses and high levels of target inhibition of PRMT5...